Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.

Public health a worry; privatisation a must: Kiran Mazumdar Shaw

Speaking to CNBC-TV18 Kiran Mazumdar Shaw, CMD, Bicon, said that India still has a long way to go on the infrastructure front. “Public health is a major worry; it is under invested.” Mohandas Pai also spoke to the channel.

Trastuzumab marketing approval may come in 12-18 months: Biocon

The European Medicines Agency (EMA) has accepted to review Mylan and Biocon‘s application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.

Will scale up contract mfg; $200 mn capex for key arms: Syngene

Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.

Strong biologics performance boosted Q1: Biocon CMD Kiran Shaw

The most important news that everyone will be tracking is when we submit dossiers in Europe and US for insulin Glargine and that as we have indicated will happen this fiscal, says Kiran Mazumdar Shaw

Pharma cos have increased focus on quality controls: Biocon CMD

A facility of biopharmaceuticals firm Biocon has cleared inspection by the US FDA

Drug to treat eye disease won't hit mkt before 2-3 yrs: Biocon

Early trials have indicated a positive data for the drug QPI-1007 to treat nonarteritic anterior ischemic optic neuropathy (NAION), says Kiran Mazumdar Shaw, CMD of Boicon.

FDI in pharma via automatic route a welcome step: Biocon

The government eased foreign direct investment in pharma sector and Kiran Mazumdar Shaw of Biocon says it is a step in the right direction.

Biocon-Mylan to file 4 drug applications in FY17 under rev-share

The company is going to submit data to US FDA and European authorities for approval in a few months time, says Kiran Mazumdar Shaw, CMD, Biocon.

US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

Realisations from insulin biosimilar to start from FY17: Biocon

Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.

Insulin mfg deal with Mexican co PISA to aid US mkt shr: Biocon

Highlighting that the insulin market currently has just a handful of players and provides huge scope for growth, Kiran Mazumdar Shaw, CMD of Biocon says, the company will be filing its first insulin analogue dossier in FY17.

EU approval for making Rosuvastatin a key milestone: Biocon

Kiran Mazumdar-Shaw, Chairman of the company, expects the company to soon win approval in the US as well.

US API import ban applies only to one drug: Biocon CMD

The US government‘s decision to not allow overseas pharmaceutical companies to import active pharmaceutical ingredient (API) applies to only one particular anti retroviral drug and is not a blanket ban, Biocon CMD Kiran Mazumdar-Shaw said.

NeoBiocon partners with Novartis for diabetes drug in UAE

Speaking to CNBC-TV18, Dr Arun Chandavarkar, CEO & Joint MD, Biocon says that the company is also looking to introduce its biosimilars and insulin portfolio in the UAE.

Hedging protects co from currency volatility: Syngene's COO

Manoj Nerurkar, COO, Syngene, says he expects the company to grow in line with its second quarter results.

'There needs to be a serious rethinking on CBDT Proposal'

On Friday, the Central Bureau for Direct Taxes (CBDT) proposed a roadmap to bring corporate tax down from the current 30 percent to 25 percent by doing away with tax breaks to India Inc.

Will focus on capacity expansion, customer needs: Syngene

Peter Bains, Director & CEO of Syngene told CNBC-TV18 growing client base and expanding capacity will aid growth in future.

Eye 20% CAGR growth in future; expansion plans on: Syngene

In an interview with CNBC-TV18, Peter Bains, CEO of Syngene International says that the company will invest nearly USD 100 million for a new plant in Mangalore, which will become functional in 2018.

Need clearer FII policy for India's novel start-ups: Biocon

Kiran Mazumdar Shaw, Chairman and MD, Biocon believes India‘s innovation led growth story is what investors are buying into but foreign investors need predictability and clarity in policies and regulations.

Major progress in IPR policy, should roll out yr-end:Biocon

Kiran Mazumdar Shaw, CMD, Biocon says there is a need to protect interest and disallow monopolies like big pharma or big companies/ corporates that want to invest and take advantage of the Indian market.

Rationalising products to become specialised player: Biocon

Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.

Syngene listing likely by July, may offload 10%: Biocon

Biocon will be offloading at least 10 percent of Syngene equity as it needs funds to support some of its R&D programmes.

Will get Syngene listed in FY16, to file DRHP in Q1: Biocon

Kiran Mazumdar Shaw, Chairperson and MD, Biocon also said that Syngene has good growth prospects and sound business plan and has a baseline valuation of Rs 3,800 crore.